Whether it's the unique breadth of our integrated offering that covers Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology products; or our commitment to recognizing and rewarding people for the contribution they make - working here isn't like anywhere else.
At Galderma, we actively give our teams reasons to believe in our ambition to become the leading dermatology company in the world. With us, you have the ultimate opportunity to gain new and challenging work experiences and create an unparalleled, direct impact.
Key responsibilities
1. National access and pricing strategy
Build and own the national market access, pricing and reimbursement strategy for the Saudi portfolio, aligned with business objectives, regional pricing governance and the Vision 2030 Health Sector Transformation Program.
Translate strategy into executable national, cluster, account, tender and stakeholder plans with clear owners, timelines and KPIs; track delivery and course-correct.
Manage Saudi price positioning within the international price referencing system, taking into account the Kingdom’s role as a reference country for other markets and regional (GCC) price alignment.
Design innovative access solutions (managed entry agreements, outcomes-based and risk-sharing agreements, price-volume agreements and patient access programmes) that widen access while protecting commercial sustainability.
2. Pre-launch market shaping (6-12 months before launch)
Map national payer, policy, procurement and clinical stakeholders; shape disease awareness, treatment guidelines and the value narrative in partnership with Medical Affairs.
Align access planning with Regulatory Affairs on SFDA registration, including expedited and priority review pathways where eligible, so that pricing is secured without delay after approval.
Identify Saudi-specific evidence gaps and lead real-world evidence, epidemiology, budget impact and cost-effectiveness work relevant to national decision-makers.
Define launch price corridors and lead SFDA pricing submissions, ensuring consistency with international reference pricing, regional price governance and global launch sequencing.
Build national reimbursement, formulary and tender-inclusion plans so that eligible patients can access the product from day one.
3. Post-launch access optimisation
Drive listing on the Ministry of Health and institutional formularies and expand inclusion across health clusters, National Guard, military, security forces, specialist, university and other government hospitals through their pharmacy and therapeutics committees.
Secure inclusion in the Council of Health Insurance drug formulary and strengthen coverage with private insurers and private hospital groups in the insured segment.
Manage SFDA price re-evaluations, price reviews and lifecycle events (new indications, line extensions, new formulations) and lead loss-of-exclusivity planning ahead of generic and biosimilar entry.
4. Institutional business, tenders and contracting
Own national tender strategy end to end for NUPCO unified procurement, long-term agreements and direct institutional purchases: demand forecasting, pricing and bid approval, technical and local-content compliance, award follow-up and supply continuity.
Ensure compliance with Local Content and Government Procurement Authority requirements and integrate localisation commitments into tender and pricing strategy.
Prioritise institutional accounts by value and potential; lead contracting excellence, including agreement terms, rebates, performance reviews and coordination with the local distributor.
Partner with Commercial and Supply Chain to convert awards into patient uptake, avoid stock-outs and penalties, and deliver institutional revenue targets.
5. HEOR, value evidence and negotiation
Lead HEOR initiatives, localisation of global value dossiers, budget impact and cost-effectiveness models along with head of Market Access and submissions in line with national health…